Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Enfermedad Crónica de las Vías Aéreas, Reología Mucosa y Exacerbaciones (COPD-CARhE)

21 de septiembre de 2026 actualizado por: University Hospital, Montpellier

Enfermedad crónica de las vías respiratorias, reología de la mucosidad y exacerbaciones: un ensayo controlado aleatorizado de pacientes con EPOC

The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.

Descripción general del estudio

Descripción detallada

The secondary objectives are to compare between the 2 arms:

  • exacerbation number according to their severity (observed throughout the duration of the study);
  • the evolution of the symptoms, the rheology of the sputum, and the pulmonary function (measurements repeated every three months);
  • medication consumption and adverse events (monitored throughout the duration of the study);
  • patient trajectories during follow-up;
  • the overall clinical improvement at the end of the study and the evolution of the quality of life (measurements repeated every 3 months);
  • the change in biomarkers of interest (baseline versus end of study).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

72

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Bordeaux, Francia
        • Reclutamiento
        • University Hospitals of Bordeaux
        • Investigador principal:
          • Maéva Zysman, MD, PhD
      • Montpellier, Francia, 34925
        • Reclutamiento
        • University Hospitals of Montpellier
        • Investigador principal:
          • Jérémy Charriot, MD
        • Sub-Investigador:
          • Arnaud Bourdin, MD, PhD
        • Sub-Investigador:
          • Anne-Sophie Gamez, MD
        • Sub-Investigador:
          • Jean Romain, MD
      • Toulouse, Francia
        • Reclutamiento
        • University Hospitals of Toulouse
        • Investigador principal:
          • Laurent Guilleminault, MD
        • Sub-Investigador:
          • Alain Didier, MD, PhD
        • Sub-Investigador:
          • Danielle Brouquieres, MD
        • Sub-Investigador:
          • Nicolas Guibert, MD
        • Sub-Investigador:
          • Sandrine Pontier Marchandise, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Subjets between 40 - 85 years (included)
  • Written and signed informed consent form
  • Subjects must be able to attend all planned visits and comply with all test procedures
  • Beneficiary of or affiliated with the French social security system
  • Man or woman with chronic obstructive pulmonary disease for at least 1 year defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and validated by the clinical investigator
  • Optimal treatment according to GOLD class severity C or D recommendations
  • >=3 exacerbation (regardless of severity: mild-moderate-severe) or ≥ 1 severe exacerbations (requiring hospitalization) in the past 12 months
  • Spontaneous or induced sputum production
  • Electrocardiogram: corrected distance between Q and T waves (QTC) <450 ms in men, QTC <470 ms in women
  • Normal audiogram for age or absence of contraindication to azithromycin for long course according to Oto-Rhino-Laryngological specialist opinion

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Patients who are prisoners or under other forms of judicial protection
  • Patients under any form of guardianship
  • Participation in another interventional protocol, (current or during the month preceding inclusion)
  • Received azithromycin in the past 3 months
  • Patient whose primary diagnosis is bronchial dilation based on CT scan documentation
  • Known hypersensitivity to azithromycin, erythromycin, any other macrolide, ketolide or any of the excipients of the azithromycin-based specialty used
  • Concomitant use of medication contraindicated with azithromycin (dihydroergotamine, ergotamine, cisapride, colchicine)
  • Other respiratory diseases or associated lung infections
  • Severe hepatic insufficiency and severe cholestasis (a liver biological test will be carried out if clinical suspicion)
  • Renal impairment with creatinine clearance < 40 mL/min
  • Patients with hematological malignancies who have undergone allogeneic hematopoietic stem cell transplantation
  • Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary disease) due to the presence of lactose in the specialty Zithromax.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Azithromycin according to symptoms

Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.

Patients randomized to the "standardized comparator arm" will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score <70 to homogenize practices between centers).

CASA-Q will be evaluated every 3 months.

  • If the patient has a sputum symptoms score <70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score <70.
  • If the patient has a sputum symptoms score> 70, management is not changed.
Experimental: Azithromycin according to rheology

Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.

Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score <70).

The rheology of mucus will be quantified every 3 months.

  • If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) > 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.
  • If the patient has a sputum symptoms score <70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score <70.
  • If the patient has a sputum symptoms score> 70, management is not changed.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The main outcome measure is the number of exacerbations over the 12 months of follow-up.
Periodo de tiempo: 12 months

An exacerbation is defined according to French recommendations as an "acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond [normal] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and / or oral corticosteroid therapy)."

12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Reología: módulo de elasticidad de la mucosidad (G')
Periodo de tiempo: Línea base (Día 0)
Línea base (Día 0)
Reología: módulo de elasticidad de la mucosidad (G')
Periodo de tiempo: 3 meses
3 meses
Reología: módulo de elasticidad de la mucosidad (G')
Periodo de tiempo: 6 meses
6 meses
Reología: módulo de elasticidad de la mucosidad (G')
Periodo de tiempo: 9 meses
9 meses
Reología: módulo de elasticidad de la mucosidad (G')
Periodo de tiempo: 12 meses
12 meses
Reología: el módulo viscoso (G '')
Periodo de tiempo: Línea base (Día 0)
Línea base (Día 0)
Reología: el módulo viscoso (G '')
Periodo de tiempo: 3 meses
3 meses
Reología: el módulo viscoso (G '')
Periodo de tiempo: 6 meses
6 meses
Reología: el módulo viscoso (G '')
Periodo de tiempo: 9 meses
9 meses
Reología: el módulo viscoso (G '')
Periodo de tiempo: 12 meses
12 meses
Reología: La relación G''/G'
Periodo de tiempo: Línea base (Día 0)
Línea base (Día 0)
Reología: La relación G''/G'
Periodo de tiempo: 3 meses
3 meses
Reología: La relación G''/G'
Periodo de tiempo: 6 meses
6 meses
Reología: La relación G''/G'
Periodo de tiempo: 9 meses
9 meses
Reología: La relación G''/G'
Periodo de tiempo: 12 meses
12 meses
Reología: la restricción crítica (tau-C).
Periodo de tiempo: Línea base (Día 0)
Línea base (Día 0)
Reología: la restricción crítica (tau-C).
Periodo de tiempo: 3 meses
3 meses
Reología: la restricción crítica (tau-C).
Periodo de tiempo: 6 meses
6 meses
Reología: la restricción crítica (tau-C).
Periodo de tiempo: 9 meses
9 meses
Reología: la restricción crítica (tau-C).
Periodo de tiempo: 12 meses
12 meses
Espirometría: volumen espiratorio forzado en 1 minuto (FEV1)
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Espirometría: volumen espiratorio forzado en 1 minuto (FEV1)
Periodo de tiempo: 3 meses
3 meses
Espirometría: volumen espiratorio forzado en 1 minuto (FEV1)
Periodo de tiempo: 6 meses
6 meses
Espirometría: volumen espiratorio forzado en 1 minuto (FEV1)
Periodo de tiempo: 9 meses
9 meses
Espirometría: volumen espiratorio forzado en 1 minuto (FEV1)
Periodo de tiempo: 12 meses
12 meses
Espirometría: capacidad vital forzada (FVC)
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Espirometría: capacidad vital forzada (FVC)
Periodo de tiempo: 3 meses
3 meses
Espirometría: capacidad vital forzada (FVC)
Periodo de tiempo: 6 meses
6 meses
Espirometría: capacidad vital forzada (FVC)
Periodo de tiempo: 9 meses
9 meses
Espirometría: capacidad vital forzada (FVC)
Periodo de tiempo: 12 meses
12 meses
Espirometría: FEV1/FVC
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Espirometría: FEV1/FVC
Periodo de tiempo: 3 meses
3 meses
Espirometría: FEV1/FVC
Periodo de tiempo: 6 meses
6 meses
Espirometría: FEV1/FVC
Periodo de tiempo: 9 meses
9 meses
Espirometría: FEV1/FVC
Periodo de tiempo: 12 meses
12 meses
Pletismografía para volúmenes pulmonares: volumen residual (RV)
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Pletismografía para volúmenes pulmonares: volumen residual (RV)
Periodo de tiempo: 3 meses
3 meses
Pletismografía para volúmenes pulmonares: volumen residual (RV)
Periodo de tiempo: 6 meses
6 meses
Pletismografía para volúmenes pulmonares: volumen residual (RV)
Periodo de tiempo: 9 meses
9 meses
Pletismografía para volúmenes pulmonares: volumen residual (RV)
Periodo de tiempo: 12 meses
12 meses
Pletismografía para volúmenes pulmonares: capacidad residual funcional (FRC)
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Pletismografía para volúmenes pulmonares: capacidad residual funcional (FRC)
Periodo de tiempo: 3 meses
3 meses
Pletismografía para volúmenes pulmonares: capacidad residual funcional (FRC)
Periodo de tiempo: 6 meses
6 meses
Pletismografía para volúmenes pulmonares: capacidad residual funcional (FRC)
Periodo de tiempo: 9 meses
9 meses
Pletismografía para volúmenes pulmonares: capacidad residual funcional (FRC)
Periodo de tiempo: 12 meses
12 meses
Pletismografía para volúmenes pulmonares: capacidad pulmonar total (TLC)
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Pletismografía para volúmenes pulmonares: capacidad pulmonar total (TLC)
Periodo de tiempo: 3 meses
3 meses
Pletismografía para volúmenes pulmonares: capacidad pulmonar total (TLC)
Periodo de tiempo: 6 meses
6 meses
Pletismografía para volúmenes pulmonares: capacidad pulmonar total (TLC)
Periodo de tiempo: 9 meses
9 meses
Pletismografía para volúmenes pulmonares: capacidad pulmonar total (TLC)
Periodo de tiempo: 12 meses
12 meses
Pletismografía para volúmenes pulmonares: RV/TLC
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Pletismografía para volúmenes pulmonares: RV/TLC
Periodo de tiempo: 3 meses
3 meses
Pletismografía para volúmenes pulmonares: RV/TLC
Periodo de tiempo: 6 meses
6 meses
Pletismografía para volúmenes pulmonares: RV/TLC
Periodo de tiempo: 9 meses
9 meses
Pletismografía para volúmenes pulmonares: RV/TLC
Periodo de tiempo: 12 meses
12 meses
Consumo de drogas a lo largo del estudio.
Periodo de tiempo: 12 meses
12 meses
El número de eventos adversos se registrará a lo largo del estudio.
Periodo de tiempo: 12 meses
12 meses
Proteína secretora de células de Serum Club
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Proteína secretora de células de Serum Club
Periodo de tiempo: 12 meses
12 meses
Bacteriología del esputo
Periodo de tiempo: Línea base (día 0)
Línea base (día 0)
Bacteriología del esputo
Periodo de tiempo: 12 meses
12 meses
The number of mild exacerbations throughout follow-up
Periodo de tiempo: 12 months

A mild exacerbation does not require new additional medicine.

12 months
The number of moderate exacerbations throughout follow-up
Periodo de tiempo: 12 months

Moderate exacerbations require antibiotics or oral corticosteroids (but not hospitalization).

12 months
The number of severe exacerbations throughout follow-up
Periodo de tiempo: 12 months

Severe exacerbations require hospitalization.

12 months
COPD Assessment Test (CAT)
Periodo de tiempo: Baseline (Day 0)

Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

Baseline (Day 0)
COPD Assessment Test (CAT)
Periodo de tiempo: 3 months

Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

3 months
COPD Assessment Test (CAT)
Periodo de tiempo: 6 months

Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

6 months
COPD Assessment Test (CAT)
Periodo de tiempo: 9 months

Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

9 months
COPD Assessment Test (CAT)
Periodo de tiempo: 12 months

Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

12 months
Sino Nasal Outcome Test 22
Periodo de tiempo: Baseline (Day 0)

The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

Baseline (Day 0)
Sino Nasal Outcome Test 22
Periodo de tiempo: 3 months

The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

3 months
Sino Nasal Outcome Test 22
Periodo de tiempo: 6 months

The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

6 months
Sino Nasal Outcome Test 22
Periodo de tiempo: 9 months

The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

9 months
Sino Nasal Outcome Test 22
Periodo de tiempo: 12 months

The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

12 months
Cough and sputum assessment questionnaire (CASA-Q)
Periodo de tiempo: Baseline (Day 0)

The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

Baseline (Day 0)
Cough and sputum assessment questionnaire (CASA-Q)
Periodo de tiempo: 3 months

The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

3 months
Cough and sputum assessment questionnaire (CASA-Q)
Periodo de tiempo: 6 months

The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

6 months
Cough and sputum assessment questionnaire (CASA-Q)
Periodo de tiempo: 9 months

The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

9 months
Cough and sputum assessment questionnaire (CASA-Q)
Periodo de tiempo: 12 months

The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

12 months
Visual analogue scale for dyspnea
Periodo de tiempo: Baseline (Day 0)

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

Baseline (Day 0)
Visual analogue scale for dyspnea
Periodo de tiempo: 3 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

3 months
Visual analogue scale for dyspnea
Periodo de tiempo: 6 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

6 months
Visual analogue scale for dyspnea
Periodo de tiempo: 9 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

9 months
Visual analogue scale for dyspnea
Periodo de tiempo: 12 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

12 months
Visual analogue scale for coughing
Periodo de tiempo: Baseline (Day 0)

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

Baseline (Day 0)
Visual analogue scale for coughing
Periodo de tiempo: 3 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

3 months
Visual analogue scale for coughing
Periodo de tiempo: 6 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

6 months
Visual analogue scale for coughing
Periodo de tiempo: 9 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

9 months
Visual analogue scale for coughing
Periodo de tiempo: 12 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

12 months
Visual analogue scale for sputum production
Periodo de tiempo: Baseline (Day 0)

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

Baseline (Day 0)
Visual analogue scale for sputum production
Periodo de tiempo: 3 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

3 months
Visual analogue scale for sputum production
Periodo de tiempo: 6 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

6 months
Visual analogue scale for sputum production
Periodo de tiempo: 9 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

9 months
Visual analogue scale for sputum production
Periodo de tiempo: 12 months

A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

12 months
Episodes of exacerbation throughout the study
Periodo de tiempo: 12 months

For each exacerbation, the beginning and end dates will be recorded.

12 months
Episodes of hospitalization throughout the study
Periodo de tiempo: 12 months

For each hospitalization, the beginning and end dates will be recorded.

12 months
Clinical improvement
Periodo de tiempo: 12 months

Clinical improvement is scored via a point system from 0 to 3 at the end of the study. The points are added-up as follows:

  • 1 point: no more than one exacerbation without hospitalization during the 52 weeks of follow-up;
  • 1 point: gain > 100mL in pre-bronchodilator FEV1 at the 52nd week compared to the baseline state;
  • 1 point: variation of the CAT score during the 52 weeks of observation > 2.
12 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
Periodo de tiempo: Baseline (day 0)

The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Baseline (day 0)
Medical outcomes study 36-Item Short Form Survey (SF-36)
Periodo de tiempo: 3 months

The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

3 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
Periodo de tiempo: 6 months

The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

6 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
Periodo de tiempo: 9 months

The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

9 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
Periodo de tiempo: 12 months

The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

12 months
EQ-5D-5L
Periodo de tiempo: Baseline (day 0)

In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

Baseline (day 0)
EQ-5D-5L
Periodo de tiempo: 3 months

In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

3 months
EQ-5D-5L
Periodo de tiempo: 6 months

In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

6 months
EQ-5D-5L
Periodo de tiempo: 9 months

In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

9 months
EQ-5D-5L
Periodo de tiempo: 12 months

In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

12 months
St-George's Respiratory Questionnaire
Periodo de tiempo: Baseline (day 0)

Scores range from 0 to 100, with higher scores indicating more limitations.

Baseline (day 0)
St-George's Respiratory Questionnaire
Periodo de tiempo: 3 months

Scores range from 0 to 100, with higher scores indicating more limitations.

3 months
St-George's Respiratory Questionnaire
Periodo de tiempo: 6 months

Scores range from 0 to 100, with higher scores indicating more limitations.

6 months
St-George's Respiratory Questionnaire
Periodo de tiempo: 9 months

Scores range from 0 to 100, with higher scores indicating more limitations.

9 months
St-George's Respiratory Questionnaire
Periodo de tiempo: 12 months

Scores range from 0 to 100, with higher scores indicating more limitations.

12 months
Blood cell differential: neutrophil levels
Periodo de tiempo: Baseline (day 0)

A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

Baseline (day 0)
Blood cell differential: eosinophil levels
Periodo de tiempo: Baseline (day 0)

A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

Baseline (day 0)
Blood cell differential: neutrophil levels
Periodo de tiempo: 12 months

A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

12 months
Blood cell differential: eosinophil levels
Periodo de tiempo: 12 months

A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Director de estudio: Jérémy Charriot, MD, University Hospital, Montpellier

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de febrero de 2023

Finalización primaria (Estimado)

1 de febrero de 2027

Finalización del estudio (Estimado)

1 de febrero de 2027

Fechas de registro del estudio

Enviado por primera vez

2 de abril de 2020

Primero enviado que cumplió con los criterios de control de calidad

5 de abril de 2020

Publicado por primera vez (Actual)

9 de abril de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The general goal is to make the study data available to interested researchers as well as to provide proof of transparency for the study. Data (and an accompanying data dictionary) will be de-identified and potentially further cleaned or aggregated as the investigators deem necessary to protect participant anonymity.

Data will be made available to persons who address a reasonable request to the study director and fulfil the requirements stipulated by the French CNIL (Commission Nationale de l'Informatique et des Libertés : https://www.cnil.fr/professionnel).

Marco de tiempo para compartir IPD

As close to "real time" as possible, the following supporting information will be made public:

  • Study Protocol (to be published in an appropriate journal).
  • Statistical Analysis Plan
  • Participant Information materials
  • Analytic code

These will be posted and registered on osf.io and/or clinicaltrials.gov (if not published).

Datasets can be requested after the publication process has been completed.

Criterios de acceso compartido de IPD

The conditions under which members of the public will be granted access to datasets are:

  • The data will be used/examined in a not-for-profit manner;
  • The data will not be used in an attempt to identify a participant or group of participants;
  • The user does not work for a private insurance company;
  • The data will not be used in support of any kind of private insurance policy or health penalties;
  • The data will be used/examined for the advancement of science/teaching while respecting participant/patient privacy and rights;
  • The user will state why they wish to access the data.
  • The appropriate CNIL approval has been obtained by the user.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir